Form 4: Arcellx Director Olivia C. Ware Reports Merger-Related Transactions

Director Olivia C. Ware of Arcellx, Inc. has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Summary

• Olivia C. Ware, a Director at Arcellx, Inc., has filed a Form 4 reporting transactions following the company's merger with Gilead Sciences, Inc.
• The merger, effective February 22, 2026, involved Arcellx becoming a wholly owned subsidiary of Gilead Sciences.
• Outstanding Arcellx stock options were canceled and converted into a right to receive a cash payment and contingent value rights.
• The cash payment is calculated as the excess of the closing amount ($115 per share) over the option's exercise price, multiplied by the number of shares subject to the option.
• Each share subject to the option also converted into one contractual contingent value right.
• Ware's filing details several stock options with exercise prices ranging from $7.61 to $63.68, all of which were subject to these conversion terms.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the mechanics of stock option conversion following a merger, which is a standard procedure and does not inherently indicate positive or negative performance of the underlying business.

Positives

• The merger with Gilead Sciences provides a significant event for Arcellx shareholders and option holders.
• The conversion of stock options into cash payments and contingent value rights offers immediate value realization for option holders.
• The filing indicates a clear process for valuing and compensating option holders based on the merger terms.

Negatives

• The cancellation of existing stock options, even with conversion, represents a change in the form of potential equity participation for option holders.
• The value of the contingent value rights is not specified and will depend on future events or milestones, introducing uncertainty.

Risks

• The value of the contingent value rights is subject to future performance and may not materialize as expected.
• The merger itself carries inherent integration risks for both Arcellx and Gilead Sciences.

Future Outlook

The future outlook for the contingent value rights is dependent on the terms outlined in the merger agreement and future performance milestones, which are not detailed in this filing.

Management Comments

• The filing details the conversion of stock options into cash payments and contingent value rights as per the merger agreement.
• Each outstanding Company stock option was canceled and converted into the right to receive a cash payment and one contractual contingent value right per share subject to the option.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome for executive and director stock options in the event of a merger or acquisition, where existing equity awards are typically cashed out or converted into rights related to the acquiring entity or the transaction's value.

Stakeholder Impact

• Shareholders: The merger with Gilead Sciences represents a significant change in ownership and potential value realization.
• Option Holders: Holders of Arcellx stock options will receive cash payments and contingent value rights, providing a form of liquidity and potential future value.
• Employees: Employees may experience changes in their roles, benefits, and equity compensation structures under Gilead Sciences' ownership.

Next Steps

• Shareholders and option holders will receive cash payments and contingent value rights as per the merger agreement.
• Arcellx will operate as a wholly owned subsidiary of Gilead Sciences.

Key Dates

Keywords

Arcellx, ACLX, Form 4, Merger, Gilead Sciences, Stock Options, Olivia C. Ware, SEC Filing, Beneficial Ownership, Contingent Value Rights